Diabetes Plus China Equals Lilly’s Emerging Markets Strategy
This article was originally published in PharmAsia News
Eli Lilly Emerging Markets President Jacques Tapiero told the Morgan Stanley Healthcare Conference that China is a “must win”, backed by diabetes brands and a near-term pipeline.
You may also be interested in...
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.